| abstract |
Pharmaceutically effective dosage of 16-methylene-17a-acetoxy-19-norpregn-4-en-3,20-dione for use in the treatment of neurodegeneration in a patient or for use in the treatment of stroke in a patient , wherein said pharmaceutically effective dosage of 16-methylene-17a-acetoxy-19-norpregn-4-en-3,20-dione exerts binding to progesterone receptors and elicits biological responses induced by the progesterone receptor without interacting with the androgen receptor and without inducing biological responses of androgens or glucocorticoids, said dosage being pharmaceutically effective at 5 mg / day or less. |